Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
4.030
-0.060 (-1.47%)
Sep 16, 2025, 4:00 PM EDT - Market closed
Omeros Employees
Omeros had 202 employees as of December 31, 2024. The number of employees increased by 4 or 2.02% compared to the previous year.
Employees
202
Change (1Y)
4
Growth (1Y)
2.02%
Revenue / Employee
n/a
Profits / Employee
-$606,307
Market Cap
274.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 202 | 4 | 2.02% |
| Dec 31, 2023 | 198 | 2 | 1.02% |
| Dec 31, 2022 | 196 | -17 | -7.98% |
| Dec 31, 2021 | 213 | -64 | -23.10% |
| Dec 31, 2020 | 277 | 19 | 7.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OMER News
- 14 days ago - Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program - Business Wire
- 4 weeks ago - Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Omeros Corporation Reports Second Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 - Business Wire
- 7 weeks ago - Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering - Business Wire
- 2 months ago - Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA - Business Wire
- 3 months ago - Omeros Announces Webcast Details for Annual Meeting of Shareholders - Business Wire
- 3 months ago - Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision - Benzinga